Abstract
Menglan Zhou, Wei Kang, Qiwen Yang, Yunsong Yu, Chao Zhuo
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Clinical risk factors and antimicrobial resistance patterns of multidrug resistant Enterobacter cloacae isolates from hospitalized patients.
10.12688/f1000research.173842.1 · 2025
Sulbactam-containing beta-lactamase inhibitor combinations.
10.1111/j.1469-0691.2007.01847.x · 2008
CARD 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance database.
10.1093/nar/gkz935 · 2020
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam.
10.1128/jcm.00661-25 · 2025
Trimmomatic: A flexible trimmer for Illumina sequence data.
10.1093/bioinformatics/btu170 · 2014
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
10.1183/13993003.00239-2022 · 2022
Unresolved referenced work
2021
Unresolved referenced work
2026
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and harbouring known beta-lactamases.
10.1007/bf01645578 · 1991
An In Vitro susceptibility study of cefotaxime-sulbactam on clinical bacterial isolates from various regions in india: A comparison with Ceftriaxone-Sulbactam.
10.7759/cureus.36078 · 2023
Extensively Drug-Resistant (XDR) and Pandrug-Resistant (PDR) Acinetobacter baumannii as sentinel indicators of cumulative system-level antimicrobial pressure in iraqi burn and high-risk hospital units.
10.3390/microorganisms14050996 · 2026
Unresolved referenced work
2019
Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.
10.7860/jcdr/2014/9742.5090 · 2014
Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options.
10.3389/fcimb.2017.00055 · 2017
Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China.
10.1080/22221751.2022.2036078 · 2022
Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: Clinical and bacteriological findings in the treatment of serious bacterial infections.
10.1016/s0924-8579(96)80008-2 · 1996
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: The EUCAST approach.
10.1111/j.1469-0691.2011.03752.x · 2012
Durlobactam, a broad-spectrum serine β-lactamase inhibitor, restores sulbactam activity against acinetobacter species.
10.1093/cid/ciad095 · 2023
Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.
10.1517/14656566.9.16.2751 · 2008
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
10.1128/aac.04808-14 · 2015
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.
10.1093/jac/dkad177 · 2023
Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: Comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales.
10.1186/s12879-024-10133-5 · 2024
Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.
10.1186/s12866-022-02662-3 · 2022
Infectious diseases society of America guidance on the treatment of AmpC β-Lactamase-Producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections.
10.1093/cid/ciab1013 · 2022
Cefotaxime. An update of its pharmacology and therapeutic use.
10.2165/00003495-199040040-00008 · 1990
Genomic survey uncovers the emergence of a multidrug-resistant dominant lineage in Proteus mirabilis populations.
10.1038/s44259-026-00189-5 · 2026
Clinical observation of cefotaxime sodium and sulbactam sodium in the treatment of acute severe pulmonary infection.
2024
No additional external references are available.